NeuroSense Therapeutics Ltd. NRSN
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 94.82% | -7.17% | 75.64% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 80.49% | -22.57% | -12.93% | ||
| Operating Income | -80.49% | 22.57% | 12.93% | ||
| Income Before Tax | -78.12% | -174.74% | -1.35% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -78.12% | -174.74% | -1.35% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -78.12% | -174.74% | -1.35% | ||
| EBIT | -80.49% | 22.57% | 12.93% | ||
| EBITDA | -80.83% | 22.57% | 46.20% | ||
| EPS Basic | -50.89% | -96.20% | 19.64% | ||
| Normalized Basic EPS | -50.88% | -- | -- | ||
| EPS Diluted | -50.89% | -96.20% | 19.64% | ||
| Normalized Diluted EPS | -50.88% | -- | -- | ||
| Average Basic Shares Outstanding | 18.05% | 40.02% | 26.12% | ||
| Average Diluted Shares Outstanding | 18.05% | 40.02% | 26.12% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||